BackAmryt Pharma Plc Overview

Amryt Pharma Plc Other Liabilities

Track Amryt Pharma Plc's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Amryt Pharma Plc Other Liabilities History

Loading

Amryt Pharma Plc vs. peers: Other Liabilities Comparison

Loading

Amryt Pharma Plc Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Amryt Pharma Plc (AMYT) FAQ

As of the most recent data (April 2023), AMYT shows a other liabilities of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMYT's other liabilities is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Amryt Pharma Plc is outperforming or lagging.

Tracking AMYT's other liabilities over time shows whether Amryt Pharma Plc is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other liabilities page, Stockcircle has Amryt Pharma Plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other liabilities (currently $0) with ownership activity and broader fundamentals.

Amryt Pharma Plc's other liabilities is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.